MDY Mdy Healthcare

RNS Number:2033S
MDY Healthcare PLC
02 March 2007



          MDY Healthcare plc participates in fundraising of Cozart plc

        Fundraising to finance acquisition of Nemesis Scientific Limited


2nd March 2007 - MDY Healthcare plc, the strategic investor in healthcare
companies, today announces that it has subscribed for #250,800 in the vendor
placing announced today by Cozart plc ("Cozart"), the medical diagnostics
company, in connection with its acquisition of Nemesis Scientific Limited ("
Nemesis"). Nemesis is a provider of workplace drug and alcohol testing services
and products to a blue-chip client base and the acquisition expands Cozart's
presence in the workplace drug testing market.


MDY Healthcare has been a shareholder in Cozart since July 2006 and, following
this placing and share purchases in the market now has an interest of
approximately 2.1% of the issued share capital of Cozart.


Commenting on the investment, Charles Spicer, CEO, said:


"We are pleased to be able to support Cozart's continuing expansion through its
acquisition of Nemesis.  Since our first investment last summer, Cozart has
produced strong financial results and continued to execute its strategic
development."



For further information, please contact:



MDY Healthcare plc
Charles Spicer, CEO
+44 (0) 207 647 1800
charles.spicer@MDYhealthcare.com



Financial Dynamics
Ben Atwell
+44 (0) 207 831 3113
ben.atwell@fd.com
John Gilbert
John.gilbert@fd.com



Notes for editors:



About MDY Healthcare

MDY Healthcare plc is a sector specialised strategic investing company quoted on
AIM (ticker symbol: MDY).  The company seeks to achieve superior returns for
shareholders by investing globally in companies, both public and private, across
the healthcare sector.  The directors, executives and senior advisors have
significant operational and investment experience in the sector and therefore
the ability to identify and review a wide range of potential investments.



Further information can be found on the website www.mdyhealthcare.com.



About Cozart



Cozart is a medical diagnostics company which develops, manufactures and sells
immunodiagnostic tests, predominantly those used for the detection of drugs of
abuse.  Cozart's products include laboratory based testing kits for the
detection of drugs in a variety of biological samples and the Cozart(R) RapiScan
and Cozart(R) DDS systems, portable devices used for the on-site testing of
drugs of abuse in saliva (oral fluid) samples. In July 2004 Cozart floated on
London's AIM (trading symbol: CZT).  Cozart has wholly owned subsidiaries in
Spain (Spinreact SA based near Barcelona); Sweden (HL Scandinavia and Medib
Scandinavien) and Italy (Cozart Italia).



Cozart supplies point of care testing products, laboratory services and forensic
testing kits to the criminal justice (e.g. police forces, probation services and
prisons), medical (e.g. hospitals and drug dependency clinics) and workplace
markets (e.g. pre-employment, random and 'for cause' testing) both in the UK and
internationally.



About Nemesis



Nemesis is a specialist provider of workplace drug and alcohol testing
solutions. The services are provided worldwide with the organisation offering a
flexible and individual approach to client needs.  Services include drug testing
policy writing and training packages covering compliance, employment law and
discipline.  A twenty-four hour call-out and sample collection service ensures
rapid sample collection within two hours of call-out.  Nemesis training packages
offer full interactive training programmes including management awareness,
E-Learning courses and award winning CD ROM packages.  Nemesis currently use
Cozart products and services as part of their offering, including the Cozart
on-site saliva test systems and laboratory services, as well as services of
other drug testing providers.  Nemesis complete their service offering with
access to a comprehensive support and rehabilitation network including full
medical review.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCIIFVAVDIFIID

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024